{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:29:24Z","timestamp":1775766564274,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Italia S.p.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioengineering"],"abstract":"<jats:p>Growing evidence suggests that impaired gut permeability and gut microbiota alterations are involved in the pathogenesis of Inflammatory Bowel Diseases (IBDs), which include Ulcerative Colitis (UC) and Crohn\u2019s Disease (CD). Vedolizumab is an anti-\u03b14\u03b27 antibody approved for IBD treatment, used as the first treatment or second-line therapy when the first line results in inadequate effectiveness. The aim of this study is to develop a mathematical model capable of describing the pathophysiological mechanisms of Vedolizumab treatment in IBD patients. In particular, the relationship between drug concentration in the blood, colonic mucosal permeability and fecal microbiota composition was investigated and modeled to detect and predict trends in order to support and tailor Vedolizumab therapies. To pursue this aim, clinical data from a pilot study on a cluster of 11 IBD patients were analyzed. Enrolled patients underwent colonoscopy in three phases (before (t0), after 24 weeks of (t1) and after 52 weeks of (t2\u00a0) Vedolizumab treatment) to collect mucosal biopsies for transepithelial electrical resistance (TEER) evaluation (permeability to ions), intestinal permeability measurement and histological analysis. Moreover, fecal samples were collected for the intestinal microbiota analysis at the three time points. The collected data were compared to those of 11 healthy subjects at t0, who underwent colonoscopy for screening surveillance, and used to implement a three-compartmental mathematical model (comprising central blood, peripheral blood and the intestine). The latter extends previous evidence from the literature, based on the regression of experimental data, to link drug concentration in the peripheral blood compartment with Roseburia abundance and intestinal permeability. The clinical data showed that Vedolizumab treatment leads to an increase in TEER and a reduction in intestinal permeability to a paracellular probe, improving tissue inflammation status. Microbiota analysis showed increasing values of Roseburia, albeit not statistically significant. This trend was adequately reproduced by the mathematical model, which offers a useful tool to describe the pathophysiological effects of Vedolizumab therapy on colonic mucosal permeability and fecal microbiota composition. The model\u2019s satisfactory predictive capabilities and simplicity shed light on the relationship between the drug, the microbiota and permeability and allow for its straightforward extension to diverse therapeutic conditions.<\/jats:p>","DOI":"10.3390\/bioengineering11070710","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T11:28:03Z","timestamp":1720783683000},"page":"710","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mathematical Modeling of Vedolizumab Treatment\u2019s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6921-6776","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Ambrosio","sequence":"first","affiliation":[{"name":"Unit of Chemical-Physics Fundamentals in Chemical Engineering, Department of Science and Technology for Sustainable Development and One Health, University Campus Bio-Medico of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Altomare","sequence":"additional","affiliation":[{"name":"Department of Sciences and Technology of Sustainable Development and Human Health, Universit\u00e0 Campus Biomedico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy"},{"name":"Gastroenterology Research Unit, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1744-6903","authenticated-orcid":false,"given":"Tamara","family":"Boscarino","sequence":"additional","affiliation":[{"name":"Unit of Chemical-Physics Fundamentals in Chemical Engineering, Department of Science and Technology for Sustainable Development and One Health, University Campus Bio-Medico of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-2718","authenticated-orcid":false,"given":"Manuele","family":"Gori","sequence":"additional","affiliation":[{"name":"Gastroenterology Research Unit, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy"},{"name":"Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), International Campus \u201cA. Buzzati-Traverso\u201d, Via E. Ramarini 32, Monterotondo Scalo, 00015 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Balestrieri","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Fondazione Policlinico Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-2830","authenticated-orcid":false,"given":"Lorenza","family":"Putignani","sequence":"additional","affiliation":[{"name":"Units of Microbiomics and Human Microbiome, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Piazza Sant\u2019Onofrio 4, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4204-4736","authenticated-orcid":false,"given":"Federica","family":"Del Chierico","sequence":"additional","affiliation":[{"name":"Unit of Human Microbiome, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Piazza Sant\u2019Onofrio 4, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-1500","authenticated-orcid":false,"given":"Simone","family":"Carotti","sequence":"additional","affiliation":[{"name":"Microscopic and Ultrastructural Anatomy Research Unit, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cicala","sequence":"additional","affiliation":[{"name":"Gastroenterology Research Unit, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy"},{"name":"Microscopic and Ultrastructural Anatomy Research Unit, Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Pier Luca","family":"Guarino","sequence":"additional","affiliation":[{"name":"Gastroenterology Research Unit, Universit\u00e0 Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy"},{"name":"Gastroenterology Unit, Fondazione Policlinico Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-3938","authenticated-orcid":false,"given":"Vincenzo","family":"Piemonte","sequence":"additional","affiliation":[{"name":"Unit of Chemical-Physics Fundamentals in Chemical Engineering, Department of Science and Technology for Sustainable Development and One Health, University Campus Bio-Medico of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"ref_1","first-page":"1077","article-title":"Gut Barrier in Health and Disease: Focus on Childhood","volume":"19","author":"Viggiano","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_2","first-page":"70","article-title":"Il Lume Intestinale e La Sclerosi Multipla","volume":"3","author":"Busillo","year":"2020","journal-title":"Sclerosi Mult. Inf. Lett. Evidenze"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Farr\u00e9, R., Fiorani, M., Abdu Rahiman, S., and Matteoli, G. (2020). Intestinal Permeability, Inflammation and the Role of Nutrients. Nutrients, 12.","DOI":"10.3390\/nu12041185"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3945\/jn.110.135657","article-title":"Regulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components1,2","volume":"141","author":"Ulluwishewa","year":"2011","journal-title":"J. Nutr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00015.2003","article-title":"Regulation of Adherens Junctions and Epithelial Paracellular Permeability: A Novel Function for Polyamines","volume":"285","author":"Guo","year":"2003","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gori, M., Altomare, A., Cocca, S., Solida, E., Ribolsi, M., Carotti, S., Rainer, A., Francesconi, M., Morini, S., and Cicala, M. (2020). Palmitic Acid Affects Intestinal Epithelial Barrier Integrity and Permeability In Vitro. Antioxidants, 9.","DOI":"10.3390\/antiox9050417"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.revmed.2015.12.012","article-title":"Le Microbiote Intestinal: Description, R\u00f4le et Implication Physiopathologique","volume":"37","author":"Landman","year":"2016","journal-title":"Rev. Med. Interne"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human Gut Microbiota\/Microbiome in Health and Diseases: A Review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie Leeuwenhoek"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1042\/BCJ20160510","article-title":"Introduction to the Human Gut Microbiota","volume":"474","author":"Thursby","year":"2017","journal-title":"Biochem. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the Normal Gut Microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3748\/wjg.v11.i8.1131","article-title":"Spatial Organization of Bacterial Flora in Normal and Inflamed Intestine: A Fluorescence in Situ Hybridization Study in Mice","volume":"11","author":"Swidsinski","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"G559","DOI":"10.1152\/ajpgi.00066.2017","article-title":"Changes in Intestinal Microbiota Composition and Metabolism Coincide with Increased Intestinal Permeability in Young Adults under Prolonged Physiological Stress","volume":"312","author":"Karl","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1634-7358(20)43343-1","article-title":"Microbiota Intestinale, Pre-e Probiotici","volume":"22","author":"Marteau","year":"2020","journal-title":"EMC-AKOS-Trattato Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global Burden of Inflammatory Bowel Disease","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and Preventing the Global Increase of Inflammatory Bowel Disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-Intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-Anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s Disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clnu.2005.02.009","article-title":"Aetiology of Inflammatory Bowel Disease (IBD): Role of Intestinal Microbiota and Gut-Associated Lymphoid Tissue Immune Response","volume":"24","author":"Maldonado","year":"2005","journal-title":"Clin. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/med.21601","article-title":"The Role of Integrins in the Pathogenesis of Inflammatory Bowel Disease: Approved and Investigational Anti-integrin Therapies","volume":"40","author":"Dotan","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-Integrin Therapy for Inflammatory Bowel Disease","volume":"24","author":"Park","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4049\/immunohorizons.2200009","article-title":"MAdCAM-1 Costimulates T Cells through Integrin A4\u03b27 to Cause Gene Expression Events Resembling Costimulation through CD28","volume":"6","author":"DeBerg","year":"2022","journal-title":"Immunohorizons"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review Article: Loss of Response to Anti-TNF Treatments in Crohn\u2019s Disease","volume":"33","author":"Chowers","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Anti-TNF Therapy in Crohn\u2019s Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082244"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood-2003-03-0957","article-title":"LPAM (A4\u03b27 Integrin) Is an Important Homing Integrin on Alloreactive T Cells in the Development of Intestinal Graft-versus-Host Disease","volume":"103","author":"Petrovic","year":"2004","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"175628481877278","DOI":"10.1177\/1756284818772786","article-title":"Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease: Current Data and Future Directions","volume":"11","author":"Ward","year":"2018","journal-title":"Therap Adv. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13318-022-00804-6","article-title":"Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects","volume":"48","author":"Xie","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-Ranging Study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40261-016-0437-4","article-title":"Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers","volume":"36","author":"Rosario","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s10620-018-4924-8","article-title":"Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease","volume":"63","author":"Boden","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ibd\/izy077","article-title":"Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s","volume":"24","author":"Binder","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jps.2600721003","article-title":"Physiologically Based Pharmacokinetic Modeling: Principles and Applications","volume":"72","author":"Gerlowski","year":"1983","journal-title":"J. Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/pan.12995","article-title":"An Introduction to Physiologically-Based Pharmacokinetic Models","volume":"26","author":"Upton","year":"2016","journal-title":"Pediatr. Anesth."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01059734","article-title":"A Review of the Applications of Physiologically Based Pharmacokinetic Modeling","volume":"7","author":"Himmelstein","year":"1979","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.41","article-title":"Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-4274(02)00374-0","article-title":"Utility of Physiologically Based Pharmacokinetic Models to Drug Development and Rational Drug Discovery Candidate Selection","volume":"138","author":"Theil","year":"2003","journal-title":"Toxicol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/FTD.0000000000000714","article-title":"Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges","volume":"42","author":"Emoto","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_39","first-page":"1","article-title":"Physiologically Based Pharmacokinetic\/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities","volume":"18","author":"Dressman","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40495-020-00212-x","article-title":"Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: An Overview","volume":"6","author":"Perry","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population Pharmacokinetics-Pharmacodynamics of Vedolizumab in Patients with Ulcerative Colitis and Crohn\u2019s Disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cicala, M., Gori, M., Balestrieri, P., Altomare, A., Tullio, A., Cola, S.D., Dejongh, S., Graziani, M.G., Pagnini, C., and Carotti, S. (2024). Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115817"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.MIB.0000215091.77492.2a","article-title":"Predicting the Crohn\u2019s Disease Activity Index from the Harvey-Bradshaw Index","volume":"12","author":"Best","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nmeth.3869","article-title":"DADA2: High-Resolution Sample Inference from Illumina Amplicon Data","volume":"13","author":"Callahan","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1128\/AEM.03006-05","article-title":"Greengenes, a Chimera-Checked 16S RRNA Gene Database and Workbench Compatible with ARB","volume":"72","author":"DeSantis","year":"2006","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2004.05.026","article-title":"Transepithelial Electrical Measurements with the Ussing Chamber","volume":"3","author":"Li","year":"2004","journal-title":"J. Cyst. Fibros."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5056\/jnm20110","article-title":"Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease","volume":"27","author":"Altomare","year":"2021","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2010.08.020","article-title":"Tight Junction Modulation by Chitosan Nanoparticles: Comparison with Chitosan Solution","volume":"400","author":"Vllasaliu","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Vespa, E., D\u2019Amico, F., Sollai, M., Allocca, M., Furfaro, F., Zilli, A., Dal Buono, A., Gabbiadini, R., Danese, S., and Fiorino, G. (2022). Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040939"},{"key":"ref_52","unstructured":"Lambert, J.D. (1991). Numerical Methods for Ordinary Differential Systems, Wiley."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/ibd\/izy307","article-title":"Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis","volume":"25","author":"Battat","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00281-014-0454-4","article-title":"The Gut Microbiota and Inflammatory Bowel Disease","volume":"37","author":"Matsuoka","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/jgh.14144","article-title":"Insights into Roseburia Intestinalis Which Alleviates Experimental Colitis Pathology by Inducing Anti-inflammatory Responses","volume":"33","author":"Shen","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000441768","article-title":"Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn\u2019s Disease","volume":"93","author":"Takahashi","year":"2016","journal-title":"Digestion"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jss.2006.07.050","article-title":"Loss of the Tight Junction Protein ZO-1 in Dextran Sulfate Sodium Induced Colitis","volume":"140","author":"Poritz","year":"2007","journal-title":"J. Surg. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbamcr.2017.03.007","article-title":"Disruption of the Epithelial Barrier during Intestinal Inflammation: Quest for New Molecules and Mechanisms","volume":"1864","author":"Lechuga","year":"2017","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/gut.2008.165670","article-title":"Impaired Intestinal Molecular Tightness in the Mucosa of Irritable Bowel Syndrome: What Are the Mediators?","volume":"58","author":"Vicario","year":"2009","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0016-5085(99)70126-5","article-title":"Altered Tight Junction Structure Contributes to the Impaired Epithelial Barrier Function in Ulcerative Colitis","volume":"116","author":"Schmitz","year":"1999","journal-title":"Gastroenterology"}],"container-title":["Bioengineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-5354\/11\/7\/710\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:52Z","timestamp":1760109352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-5354\/11\/7\/710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["bioengineering11070710"],"URL":"https:\/\/doi.org\/10.3390\/bioengineering11070710","relation":{},"ISSN":["2306-5354"],"issn-type":[{"value":"2306-5354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}